An open-label, Phase I/II, dose escalating study evaluating the safety and efficacy of EPO906, q3w, in patients with non-small cell lung cancer To determine the activity of EPO906 administered once every 3 weeks to patients with advanced NSCLC

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase I/Ib study of GWN323 alone and in combination with PDR001 in patients with advanced malignancies and lymphomas Estudio de fase I/Ib de GWN323 (anti-GITR) en monoterapia y en combinación con PDR001 (anti-PD-1) en pacientes con tumores sólidos avanzados y linfomas The purpose of this trial is to explore the clinical utility of two investigational antibodies in patients with advanced cancer or lymphomas. The dose escalation parts will estimate the MTD and/or RD...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Pharmacogenetic analysis study of hepatitis C patients treated with DEB025/Alisporivir alone or with Peg-IFN2a and/or Ribavirin To assess the impact of potential markers (or polymorphisms) in host genes from patients in studies DEB-025-103, DEB-025-HCV-203 and DEB-025-HCV-205 on the PK profile, safety, and efficacy of alispori...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A single center, phase I, partially blinded, placebo-controlled, first-in-man study to evaluate the safety, tolerability and Proof of Mechanism (PoM) of a single administration of BFH772 in healthy volunteers, and Proof of Concept (PoC) study to evaluate the safety, tolerability, and pharmacodynamics of multiple topical administrations of BFH772 in patients with psoriasis • Investigate the safety and tolerability of single and multiple doses of BFH772 in two different formulations in healthy and psoriatic subjects • Assess the efficacy of topically applied BFH772 to tr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy (PDR) To assess the long-term safety and tolerability of open-label treatment with Sandostatin LAR 30 mg in patients who completed the double-masked study CSMS995 0802

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 16-day, randomized, double-blind, double-dummy, placebo-controlled, parallel-group trial comparing lumiracoxib 100mg o.d. with naproxen 500 mg b.i.d. plus omeprazole 20mg o.d. and placebo in healthy volunteers to confirm the safety and tolerability of lumiracoxib in the small bowel The primary objective of this study is to demonstrate, by video capsule endoscopy (VCE), that the percentage of subjects with one or more small bowel mucosal breaks (with or without hemorrhage) is si...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Safety & Efficacy of BCT197A2201 in COPD patients presenting with an exacerbation • To assess the efficacy of a single and repeated dose of BCT197 in COPD patients presenting with an exacerbation measured by the improvement in FEV1 over the first 5 days of treatment relative to pla...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy Assess the effect of BHQ880 compared with placebo on time to first SRE in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations Part II: to demonstrate that the time to flare in Part II is higher with canakinumab than with placebo. Part I: to assess if canakinumab allows tapering of steroids as per protocol in at least 25% of ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of multiple oral doses of AFQ056 - To assess the efficacy of multiple oral doses of AFQ056 in reducing the global score of the Aberrant Behavior Checklist – Community Edition (ABC-C) in FXS patients. - To assess the safety and tolera...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune